Amoxicillin is a beta-lactam antibiotic that works by binding to penicillin-binding proteins (PBPs) inside the bacterial cell wall. This stops the bacteria from cross-linking their peptidoglycan chains, which is essential for building a strong cell wall. Without a functional cell wall, the bacteria cannot maintain their structural integrity, especially when they are actively dividing. Water rushes into the weak bacterial cell, causing it to swell and burst (lysis). Because it targets a structure that human cells do not have, amoxicillin selectively kills bacteria without harming human tissues.
Developed as a semi-synthetic derivative of 6-aminopenicillanic acid (6-APA), which is derived from the fungus Penicillium chrysogenum. The addition of a para-hydroxyl group to the benzyl side chain of ampicillin was designed to improve oral absorption and reduce gastrointestinal side effects.
Following the clinical success of penicillin G and the subsequent development of broad-spectrum ampicillin in the 1960s, researchers sought to overcome ampicillin's primary drawback: incomplete oral absorption and high rates of ampicillin-associated diarrhoea. In 1972, a team at the British pharmaceutical company Beecham synthesized amoxicillin by adding a hydroxyl group to the ampicillin molecule. This structural modification dramatically increased oral bioavailability and allowed for less frequent dosing. Amoxicillin was introduced to the market in 1974 and rapidly became one of the most prescribed antibiotics globally. Its inclusion on the first World Health Organization (WHO) Model List of Essential Medicines in 1977 cemented its status as a cornerstone of global public health, a position it maintains today as the most widely used antibiotic in paediatric and primary care medicine.
Broad-spectrum bacterial infections, specifically targeting respiratory and urinary tract infections where improved oral absorption over ampicillin was desired.